Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

This study combines a freezing procedure on liver tumors (cryoablation), an immune-stimulating injection (SD-101), and two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery. **You may be eligible if...** - You are 18 or older - You have been diagnosed with locally advanced or metastatic liver cancer (hepatocellular carcinoma) confirmed by biopsy or standard imaging criteria - You have at least one liver tumor that is 3 cm or larger and positioned away from major blood vessels and bile ducts - You are in good overall health **You may NOT be eligible if...** - Your liver cancer has not been confirmed by the required diagnostic criteria - Your tumor is too close to vital structures for safe treatment - You have had certain prior systemic treatments that would disqualify you per the protocol Talk to your doctor to see if this trial is right for you.